AI biotechs launch bioprospecting expeditions with Indigenous groups, agree to share benefits
By Ben Johnson,
Nature
| 02. 14. 2025
A London-based biotech has amassed the world’s largest ethically sourced foundational biodiversity database for training artificial intelligence (AI) by setting up partnerships with 25 countries around the world. The startup, Basecamp Research, announced in January the launch of a new computer cluster that will mine their rich biodiversity database — which contains species collected from extreme locations such as the Arctic tundra and African deserts — to develop new and unique proteins with commercial potential. In agreeing to share revenues from these proteins before conducting its explorations, Basecamp brings an unusual approach to commercial bioprospecting, an activity traditionally associated with injustices towards Indigenous cultures, biopiracy and colonial practices.
The age-old search for medicines derived from nature has entered a new era. Driven by the need to increase the number of proteins to better train machine-learning algorithms, commercial bioprospecting is undergoing a renaissance. Scientists are going into unexplored areas to sample the genomes and proteins of millions of species with the ultimate goal of finding better versions of what is already in nature.
AI-based design has so far been limited to...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...